New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 20, 2014
10:17 EDTISRIsoRay advances for second day after treatment used for pediatric cancer patient
Shares of IsoRay (ISR), which develops seed brachytherapy and medical radioisotope applications, are higher for a second straight session after the company announced yesterday that its technology had been used in the treatment of a pediatric patient's tumor. WHAT'S NOTABLE: IsoRay announced yesterday morning that a doctor in North Carolina had successfully completed the world's first pediatric implant using the company's Cesium-131 brachytherapy mesh. The patient was a 12 year old male who was diagnosed with recurrent metastatic Wilms tumor, which is a type of childhood kidney tumor. Radiation therapy was needed in this case to treat the surgical bed, according to the doctor, who added that designing the treatment mesh was done with the assistance of the IsoRay team and that the patient recovered normally and has been discharged home. PRICE ACTION: In morning trading today, IsoRay shares are up about 25% to $3.19. Shares had more than doubled yesterday following the company's announcement, adding $1.46, or 133.94%.
News For ISR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 22, 2015
08:29 EDTISRFBR scuttled CEL-SCI offering after 'CEO meddling,' Feuerstein says
FBR scuttled its role in a CEL-SCI (CVM) offering due to "inappropriate CEO meddling," leaving Dawson James to be "brought on to salvage something," according to TheStreet's Adam Feuerstein citing a source. The Fly notes CEL-SCI announced last night a proposed offering of common stock and warrants, with no amount given and Dawson James Securities acting as the sole placement agent on a "best efforts" basis. IsoRay (ISR) tried to raise money yesterday too, Feuerstein reported on Twitter, citing an investor source.
May 20, 2015
09:25 EDTISROn The Fly: Pre-market Movers
UP AFTER EARNINGS: American Eagle Outfitters (AEO), up 8.6%... Computer Sciences (CSC), up 4.1%. ALSO HIGHER: Sarepta Therapeutics (SRPT), up 44.5% after announcing plans for rolling eteplirsen NDA... Genocea Biosciences (GNCA), up 22.5% after GEN-003 Phase 2 trial met primary endpoint... IsoRay (ISR), up 31.7% after Cesium-131 reports 96% success in local control and 100% survival in 5 years... AVEO Pharmaceuticals (AVEO), up 15.7% after presenting results of extension study 902 and gets FDA feedback for tivozanib... Pep Boys (PBY), up 12.5% following reports that potential buyer have approached the company about a possible takeover. DOWN AFTER EARNINGS: Etsy (ETSY), down 19.5%... China Distance Education (DL), down 7.7%... Keysight Technologies (KEYS), down 5.7%.... Lowe's (LOW), down 5.2%. ALSO LOWER: Lpath (LPTN), down 75.6% after announcing that it will undergo corporate restructuring... Achillion Pharmaceuticals (ACHN), down 10.1% following collaboration for HCV with Janssen... El Pollo LoCo (LOCO), down 3.5% after 6M share Block Trade priced at $22.25... Cimarex Energy (XEC), down 3.3% after 6M share Spot Secondary priced at $109.00.
08:27 EDTISRIsoRay Cesium-131 reports 96% success in local control, 100% survival in 5 years
IsoRay announced the on-line publication of the first major peer reviewed study showing improved results using IsoRay's Cesium-131 seeds in the treatment of lung cancer. Dr. Bhupesh Parashar MD, of Weill Cornel Medical College, is lead author of the publication titled: 'Analysis of Stereotactic Radiation vs. Wedge Resection vs Wedge Resection Plus Cesium-131 Brachytherapy in Early-stage Lung Cancer'. The study noted that the survival rate at 5 years was exceptional for the Cesium-131 group, which included many high risk patients, and Cesium-131 added no noticeable side effects. Treatment with Cesium-131 was performed at the time of the surgery as a single treatment, in contrast to another treatment option, external radiation, which requires numerous hospital visits.
May 18, 2015
08:48 EDTISRIsoRay reports Q3 EPS (2c), one estimate (1c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use